Cytokines / Hematopoietic agents / Myeloid growth factors
Myeloid growth factors
Mechanism of Action
- FILGRASTIM (G-CSF) regulates the production of neutrophils within the bone marrow and affects neutrophil progenitor proliferation, differentiation and functional activation
- also mobilizes hematopoietic stem cells, increasing their concentration in peripheral blood
- led to the use of peripheral blood stem cells (PBSCs) rather than bone marrow stem cells for transplantation
- also mobilizes hematopoietic stem cells, increasing their concentration in peripheral blood
- SAGRAMOSTIM (GM-CSF) stimulates myelopoiesis generally, and neutrophils and monocytes specifically
Pharmacokinetics
- PEGFILGRASTIM is a conjugation product of filgrastim with polyethylene glycol
- much long half-life
- injected once per chemotherapy cycle, instead of daily for several days
Therapeutic Uses
- cancer chemotherapy-induced neutropenia (esp. FILGRASTIM)
- esp. during autologous stem cell transplantation following high-dose chemotherapy
- objective is to prevent systemic infection (neutrophils are the 1st line of defence against infection)
- congenital neutropenia, cyclic neutropenia, myelodysplasia, and aplastic anemia
Side effects
FILGRASTIM/PEGFILGRASTIM
LIFE-THREATENING: |
|
|
---|---|---|
SERIOUS | INNOCUOUS | |
COMMON |
|
|
RARE |
|
SARGRAMOSTIM
LIFE-THREATENING: |
|
|
---|---|---|
SERIOUS | INNOCUOUS | |
COMMON |
|
|
RARE |
|